


Proteomics International Signs Agreement to Commercialise Kidney Disease Diagnostic in China

PI has recently validated a new, proteomics derived diagnostic test for the early diagnosis of diabetic kidney disease (DKD) and has finalised a \$1.1million agreement with Chinese bio-pharmaceutical company New Summit Biopharma to commercialise the test in China.



This is the first commercial agreement for PI's diabetic kidney disease diagnostic, and also the first-ever proteomics derived In-vitro Diagnostic (IVD) to enter the massive Chinese market. According to the WHO, 9% of the Chinese population, or 120 million people already have diabetes. The agreement is a significant milestone for the company, and offers the potential to provide earlier diagnosis and improved treatment of kidney disease, the major complication of diabetes. [Media release](#)


Please click here for more information on PI's biomarker [discovery pipeline](#) and [discovery services](#).

Strong Demand for Proteomics International Analytical Services

PI has recently expanded its client base to the Middle East region securing a major contract for its accredited analytical testing of generic medicines (biosimilars). The company was the world's first to obtain ISO 17025 accreditation in proteomics, the leading standard used by US Federal Testing Laboratories. PI's protein analysis services are used from medical research through to improving quality control of food products.

20th Annual Lorne Proteomics Conference – Proteomics International Launches New Assay for Oxidative Stress – 2tag Assay Kits

PI has developed a unique test that directly measures the effect of oxidative stress on proteins. This patented test, called "2tag", builds on PI's existing technology platform to zoom even further into the molecular landscape of proteins.



Oxidative stress initially causes reversible changes to protein function but later damages the proteins themselves. The new 2tag assay kits are able to measure these reversible changes (protein thiol oxidation) before damage occurs, allowing for early detection and treatment of oxidative stress. The test can also be adapted to assist in the detailed characterisation of the structure of protein-based drugs (biosimilars). Click [here](#) for more information.

PI invites expressions of interest from groups who wish to beta-test this service - please email info@proteomics.com.au

IPO to close soon

The Company's initial public share offer to list on the Australian Stock Exchange launched last year will close next week. The process was put on hold due to the diagnostics deal in China, and since then has attracted considerable interest from the investment community.

Proteomics International Laboratories Ltd (PILL), the new parent company of Proteomics International, is raising a minimum of \$3 million to fund the growth of its three business units - analytics, diagnostics and therapeutics.

The offer remains open to the public and applications are invited up until 27 February 2015. For further information or to obtain an prospectus please click [here](#).

Contact us:

Website: Proteomics International
E-mail: info@proteomics.com.au

Agents:

Japan – Leave a Nest Co. Ltd – info@leaveanest.com
China & Hong Kong – Asia Bio Channel Limited – bcoissac@asiabiotech.com
India – KAN-THT Pvt Ltd – bioservices@kan-tht.com
Malaysia/ Indonesia/ Thailand – First BASE Laboratories S/B – peptide-my@base-asia.com
Singapore – Axil Scientific Pte Ltd – peptide@axilscientific.com